What is IGeneX?
IGeneX is a specialized diagnostic testing company headquartered in Milpitas, California. The firm focuses on providing comprehensive testing solutions for Lyme disease and other tick-borne illnesses. By offering convenient collection kits to both patients and healthcare providers, IGeneX facilitates accurate identification of various tick-borne pathogens. The company has established a robust reputation for its thorough diagnostic methodologies, serving a diverse clientele across the United States, including individuals, medical practitioners, and employers seeking reliable diagnostic services.
How much funding has IGeneX raised?
IGeneX has raised a total of $1.2M across 2 funding rounds:
Debt
$350K
Debt
$870K
Debt (2020): $350K with participation from PPP
Debt (2021): $870K led by PPP
Key Investors in IGeneX
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for IGeneX?
The recent major strategic investment in IGeneX signals a pivotal moment for the company, likely enabling expansion of its diagnostic capabilities and market reach. This enterprise-level funding suggests a focus on scaling operations, enhancing research and development for new diagnostic markers, and potentially broadening its service offerings beyond tick-borne diseases. IGeneX is poised to further solidify its leadership in specialized diagnostics, leveraging this capital infusion to drive innovation and meet growing demand for accurate disease detection.
See full IGeneX company page
